BioSpace News Archive

CCRF recently awarded two promising scientists the Emerging Scientist Award at the University of Minnesota.

Arcellx, Inc. (NASDAQ: ACLX), today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 3:30 p.m. ET.

Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it will participate in two upcoming investor conferences.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), today announced that the Company’s Chief Financial Officer, Johanna Mylet, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY from September 12-14, 2022.

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York.

NANOBIOTIX (Euronext: NANO – Nasdaq: NBTX), and LianBio (Nasdaq: LIAN), today announced randomization of the first patient in Asia in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (“LA-HNSCC”) who are ineligible for platinum-based chemotherapy.

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2022 financial results on Thursday, October 27, 2022 at 7:30 a.m. Central Time.

DBV Technologies Announces Initiation of Phase 3 Study(VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years.

SQZ Biotechnologies Company announced that Armon Sharei, Ph.D., Chief Executive Officer and Founder at SQZ Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 and at the Chardan 6th Annual Genetic Medicines Conference on October 4.

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease that declines with combination immunosuppressive therapy.